Hypertensive cardiac remodeling in males and females: From the bench to the bedside

Hypertension

Volumn 49, Issue 3, 2007, Pages 401-407

  Deschepper, Christian F ^a   Llamas, Bastien ^b  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; DAIDZEIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUTAMIDE; GENISTEIN; GLUCOCORTICOID; PHYTOESTROGEN; STEROID; TESTOSTERONE;

ALCOHOLIC CARDIOMYOPATHY; ANTIHYPERTENSIVE ACTIVITY; CALCIUM CELL LEVEL; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; ESTROGEN ACTIVITY; ESTROGEN THERAPY; GENE DOSAGE; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; HEART HYPERTROPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE MASS; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; QT INTERVAL; RECEPTOR GENE; SEX DIFFERENCE; SHORT SURVEY; TORSADE DES POINTES; X CHROMOSOME; Y CHROMOSOME;

ANDROGENS; ESTROGENS; FEMALE; HUMANS; HYPERTENSION; MALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RECEPTORS, STEROID; SEX CHROMOSOMES; SEX FACTORS; VENTRICULAR REMODELING;

EID: 33847052869     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000256279.49882.d8     Document Type: Short Survey

References (96)

1. Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov. 2006;5:425-239.
2. Du XJ, Fang L, Kiriazis H. Sex dimorphism in cardiac pathophysiology: experimental findings, hormonal mechanisms, and molecular mechanisms. Pharmacol Ther. 2006;111:434-475.
3. Sheifer SE, Canos MR, Weinfurt KP, Arora UK, Mendelsohn FO, Gersh BJ, Weissman NJ. Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J. 2000;139:649-653.
4. Trepanier-Boulay V, St Michel C, Tremblay A, Fiset C. Gender-based differences in cardiac repolarization in mouse ventricle. Circ Res. 2001;89:437-444.
5. Pham TV, Robinson RB, Danilo P, Jr, Rosen MR. Effects of gonadal steroids on gender-related differences in transmural dispersion of L-type calcium current. Cardiovasc Res. 2002;53:752-762.
6. Boheler KR, Volkova M, Morrell C, Garg R, Zhu Y, Margulies K, Seymour A-M, Lakatta EG. Sex- and age-dependent human transcriptome variability: implications for chronic heart failure. Proc Natl Acad Sci U S A. 2003;100:2754-2759.
7. Capasso JM, Remily RM, Smith RH, Sonnenblick EH. Sex differences in myocardial contractility in the rat. Basic Res Cardiol. 1983;78:156-171.
8. Schaible TF, Scheuer J. Comparison of heart function in male and female rats. Basic Res Cardiol. 1984;79:402-412.
9. Weinberg EO, Thienelt CD, Katz SE, Bartunek J, Tajima M, Rohrbach S, Douglas PS, Lorell BH. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol. 1999;34:264-273.
10. Douglas PS, Katz SE, Weinberg EO, Chen MH, Bishop SP, Lorell BH. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol. 1998;32:1118-1125.
11. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail. 2002;8:101-107.
12. Litwin SE, Katz SE, Litwin CM, Morgan JP, Douglas PS. Gender differences in postinfarction left ventricular remodeling. Cardiology. 1999;91:173-183.
13. Cavasin MA, Sankey SS, Yu A-L, Menon S, Yang X-P. Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol. 2003;284:H1560-H1569.
14. Gao XM, Xu Q, Kiriazis H, Dart AM, Du XJ. Mouse model of post-infarct ventricular rupture: time course, strain- and gender-dependency, tensile strength, and histopathology. Cardiovasc Res. 2005;65:469-477.
15. Leri A, Kajstura J, Li B, Sonnenblick EH, Beltrami CA, Anversa P, Frishman WH. Cardiomyocyte aging is gender-dependent: the local IGF-1-IGF-1R system. Heart Dis. 2000;2:108-115.
16. Leri A, Malhotra A, Liew CC, Kajstura J, Anversa P. Telomerase activity in rat cardiac myocytes is age and gender dependent. J Mol Cell Cardiol. 2000;32:385-390.
17. Leinwand LA. Sex is a potent modifier of the cardiovascular system. J Clin Invest. 2003;112:302-307.
18. Du X-J. Gender modulates cardiac pheotype development in genetically modified mice. Cardiovasc Res. 2004;63:510-519.
19. Frey N, McKinsey TA, Olson EN. Decoding calcium signals involved in cardiac growth and function. Nature Medicine. 2000;6:1221-1227.
20. Curl CL, Wendt IR, Kotsanas G. Effects of gender on intracellular. Pflugers Arch. 2001;441:709-716.
21. Chen J, Petranka J, Yamamura K, London RE, Steenbergen C, Murphy E. Gender differences in sarcoplasmic reticulum calcium loading after isoproterenol. Am J Physiol Heart Circ Physiol. 2003;285:H2657-H2662.
22. Weinberg EO, Mirotsou M, Gannon J, Dzau VJ, Lee RT, Pratt RE. Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol Genomics. 2003;12:113-127.
23. Aurigemma GP, Gaasch WH. Gender differences in older patients with pressure-overload hypertrophy of the left ventricle. Cardiology. 1995;86:310-317.
24. Villari B, Campbell SE, Schneider J, Vassalli G, Chiariello M, Hess OM. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J. 1995;16:1410-1419.
25. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol. 1993;72:310-313.
26. Hayward CS, Webb CM, Collins P. Effect of sex hormones on cardiac mass. Lancet. 2001;357:1354-1356.
27. Olivetti G, Giordano G, Corradi D, Melissari M, Lagrasta C, Gambert SR, Anversa P. Gender differences and aging: effects on the human heart. J Am Coll Cardiol. 1995;26:1068-1079.
28. Malcolm DD, Burns TL, Mahoney LT, Lauer RM. Factors affecting left ventricular mass in childhood: the Muscatine Study. Pediatrics. 1993;92:703-709.
29. Punnonen R, Jokela H, Aine R, Teisala K, Salomaki A, Uppa H. Impaired ovarian function and risk factors for atherosclerosis in premenopausal women. Maturitas. 1997;27:231-238.
30. Grohe C, Kahlert S, Lobbert K, Stimpel M, Karas RH, Vetter H, Neyses L. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett. 1997;416:107-112.
31. Brandenburger Y, Jenkins A, Autelitano DJ, Hannan RD. Increased expression of UBF is a critical determinant for rRNA synthesis and hypertrophic growth of cardiac myocytes. FASEB J. 2001;15:2051-2053.
32. Brower GL, Gardner JD, Janicki JS. Gender mediated cardiac protection from adverse ventricular remodeling is abolished by ovariectomy. Mol Cell Biochem. 2003;251:89-95.
33. Xu Y, Arenas IA, Armstrong SJ, Davidge ST. Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res. 2003;57:388-394.
34. van Eickels M, Grohe C, Cleutjens JPM, Janssen BJ, Wellens HJJ, Doevendans PAF. 17β-Estradiol attenuates the development of pressure overload hypertrophy. Circulation. 2001;104:1419-1423.
35. Smith PJ, Ornatsky O, Stewart DJ, Picard P, Dawood F, Wen WH, Liu PP, Webb DJ, Monge JC. Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation. 2000;102:2983-2989.
36. Hugel S, Reincke M, Stromer H, Winning J, Horn M, Dienesch C, Mora P, Schmidt HH, Allolio B, Neubauer S. Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling. J Am Coll Cardiol. 1999;34:1427-1434.
37. Beer S, Reincke M, Kral M, Callies F, Stromer H, Dienesch C, Steinhauer S, Ertl G, Allolio B, Neubauer S. High-dose 17beta-estradiol treatment prevents development of heart failure post-myocardial infarction in the rat. Basic Res Cardiol. 2007;102:9-18.
38. van Eickels M, Patten RD, Aronovitz MJ, Alsheikh-Ali A, Gostyla K, Celestin F, Grohe C, Mendelsohn ME, Karas RH. 17-Beta-estradiol increases cardiac remodeling and mortality in mice with myocardial infarction. J Am Coll Cardiol. 2003;41:2084-2092.
39. Pelzer T, Loza PA, Hu K, Bayer B, Dienesch C, Calvillo L, Couse JF, Korach KS, Neyses L, Ertl G. Increased mortality and aggravation of heart failure in estrogen receptor-beta knockout mice after myocardial infarction. Circulation. 2005;111:1492-1498.
40. Dubey RK, Gillespie DG, Jackson EK, Keller PJ. 17Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension. 1998;31:522-528.
41. Stewart JA, Jr, Cashatt DO, Borck AC, Brown JE, Carver WE. 17Beta-estradiol modulation of angiotensin II-stimulated response in cardiac fibroblasts. J Mol Cell Cardiol. 2006;41:97-107.
42. Hara M, Ono K, Hwang MW, Iwasaki A, Okada M, Nakatani K, Sasayama S, Matsumori A. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002;195:375-381.
43. Kennedy RH, Hauer-Jensen M, Joseph J. Cardiac function in hearts isolated from a rat model deficient in mast cells. Am J Physiol Heart Circ Physiol. 2005;288:H632-H637.
44. Brower GL, Janicki JS. Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. J Card Fail. 2005;11:548-556.
45. Brower GL, Chancey AL, Thanigaraj S, Matsubara BB, Janicki JS. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2002;283:H518-H525.
46. Chancey AL, Gardner JD, Murray DB, Brower GL, Janicki JS. Modulation of cardiac mast cell-mediated extracellular matrix degradation by estrogen. Am J Physiol Heart Circ Physiol. 2005;289:H316-H321.
47. Modena MG, Muia N Jr, Aveta P, Molinari R, Rossi R. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension. 1999;34:1041-1046.
48. Babiker FA, De Windt LJ, van Eickels M, Thijssen V, Bronsaer RJP, Grohé C, van Bilsen M, Doevendans PAF. 17β-Estradiol antagonizes cardiomyocyte hypertrophy by autocrine/paracrine stimulation of a guanylyl cyclase A receptor-cyclic guanosine monophosphate-dependent protein kinase pathway. Circulation. 2004;109:269-276.
49. Deschepper CF, Masciotra S, Zahabi A, Boutin-Ganache I, Picard S, Reudelhuber T. Functional alterations of the Nppa promoter are linked to cardiac ventricular hypertrophy in WKY/WKHA rat crosses. Circ Res. 2001;88:222-227.
50. Rossouw JE. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res. 2002;53:550-557.
51. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24:313-340.
52. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321-333.
53. Brouillette J, Rivard K, Lizotte E, Fiset C. Sex and strain differences in adult mouse cardiac repolarization: importance of androgens. Cardiovasc Res. 2005;65:148-157.
54. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199-1208.
55. Baltatu O, Cayla C, Iliescu R, Andreev D, Bader M. Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats. Hypertension. 2003;41:830-833.
56. Iliescu R, Campos LA, Schlegel WP, Morano I, Baltatu O, Bader M. Androgen receptor independent cardiovascular action of the antiandrogen flutamide. J Mol Med. 2003;81:420-427.
57. Zaugg M, Jamali NZ, Lucchinetti E, Xu W, Alam M, Shafiq SA, Siddiqui MA. Anabolic-androgenic steroids induce apoptotic cell death in adult rat ventricular myocytes. J Cell Physiol. 2001;187:90-95.
58. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98:256-261.
59. Mendelsohn ME, Rosano GM. Hormonal regulation of normal vascular tone in males. Circ Res. 2003;93:1142-1145.
60. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-492.
61. Korytkowski MT, Krug EI, Daly MA, Deriso L, Wilson JW, Winters SJ. Does androgen excess contribute to the cardiovascular risk profile in postmenopausal women with type 2 diabetes? Metabolism. 2005;54:1626-1631.
62. Skavdahl M, Steenbergen C, Clark J, Myers P, Demianenko T, Mao L, Rockman HA, Korach KS, Murphy E. Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol. 2005;288:H469-H476.
63. Babiker FA, Lips D, Meyer R, Delvaux E, Zandberg P, Janssen B, van Eys G, Grohe C, Doevendans PA. Estrogen receptor beta protects the murine heart against left ventricular hypertrophy. Arterioscler Thromb Vasc Biol. 2006;26:1524-1530.
64. Peter I, Shearman AM, Vasan RS, Zucker DR, Schmid CH, Demissie S, Cupples LA, Kuvin JT, Karas RH, Mendelsohn ME, Housman DE, Benjamin EJ. Association of estrogen receptor beta gene polymorphisms with left ventricular mass and wall thickness in women. Am J Hypertens. 2005;18:1388-1395.
65. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. Science. 2005;308:1583-1587.
66. Meyer MR, Haas E, Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension. 2006;47:1019-1026.
67. Pugh PJ, Jones RD, Jones TH, Channer KS. Heart failure as an inflammatory condition: potential role for androgens as immune modulators. Eur J Heart Fail. 2002;4:673-680.
68. Stork S, van der Schouw YT, Grobbee DE, Bots ML. Estrogen, inflammation and cardiovascular risk in women: a critical appraisal. Trends Endocrinol Metab. 2004;15:66-72.
69. Llamas B, Jiang Z, Rainville M-L, Picard S, Deschepper CF. Distinct QTLs are linked to cardiac left ventricular mass in a sex-specific manner in a normotensive inbred rat intercross. Mamm Genome. 2005;16:700-712.
70. Souzeau E, Llamas B, Bélanger S, Deschepper CF. A genetic locus accentuates the effect of volume overload on adverse left ventricular remodeling in male and female rats. Hypertension. 2006;47:128-133.
71. Li Y, Kishimoto I, Saito Y, Harada M, Kuwahara K, Izumi T, Hamanaka I, Takahashi N, Kawakami R, Tanimoto K, Nakagawa Y, Nakanishi M, Adachi Y, Garbers DL, Fukamizu A, Nakao K. Androgen contributes to gender-related cardiac hypertrophy and fibrosis in mice lacking the gene encoding guanylyl cyclase-A. Endocrinology. 2004;145:951-958.
72. Shearman AM, Cooper JA, Kotwinski PJ, Miller GJ, Humphries SE, Ardlie KG, Jordan B, Irenze K, Lunetta KL, Schuit SC, Uitterlinden AG, Pols HA, Demissie S, Cupples LA, Mendelsohn ME, Levy D, Housman DE. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res. 2006;98:590-592.
73. Charchar FJ, Tomaszewski M, Strahorn P, Champagne B, Dominiczak AF. Y is there a risk to being male? Trends Endocrinol Metab. 2003;14:163-168.
74. Ely D, Turner M, Milsted A. Review of the Y chromosome and hypertension. Braz J Med Biol Res. 2000;33:679-691.
75. Hoit BD, Kiatchoosakun S, Restivo J, Kirkpatrick D, Olszens K, Shao H, Pao Y-H, Nadeau JH. Naturally occurring variation in cardiovascular traits among inbred strains of mice. Genomics. 2003;79:679-685.
76. Deschepper CF, Olson JL, Otis M, Gallo-Payet N. Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains. J Appl Physiol. 2004;97:369-376.
77. Llamas B, Deschepper CF. The chromosome Y contributes to features of dilated eccentric hypertrophy in male C57Bl/6J mice. Circ Res. 2005;97:E12.
78. Federman DD. The biology of human sex differences. N Engl J Med. 2006;354:1507-1514.
79. Levitt NS, Lindsay RS, Holmes MC, Seckl JR. Dexamethasone in the last week of pregnancy attenuates hippocampal glucocorticoid receptor gene expression and elevates blood pressure in the adult offspring in the rat. Neuroendocrinology. 1996;64:412-418.
80. Kudwa AE, Michopoulos V, Gatewood JD, Rissman EF. Roles of estrogen receptors alpha and beta in differentiation of mouse sexual behavior. Neuroscience. 2006;138:921-928.
81. Plut C, Ribiere C, Giudicelli Y, Dausse JP. Gender differences in hypothalamic tyrosine hydroxylase and alpha(2)-adrenoceptor subtype gene expression in cafeteria diet-induced hypertension and consequences of neonatal androgenization. J Pharmacol Exp Ther. 2002;302:525-531.
82. Tchernitchin AN, Tchernitchin NN, Mena MA, Unda C, Soto J. Imprinting: perinatal exposures cause the development of diseases during the adult age. Acta Biol Hung. 1999;50:425-440.
83. Souzeau E, Belanger S, Picard S, Deschepper CF. Dietary isoflavones during pregnancy and lactation provide cardioprotection to offspring rats in adulthood. Am J Physiol Heart Circ Physiol. 2005;289:H715-H721.
84. Gardner JD, Brower GL, Janicki JS. Effects of dietary phytoestrogens on cardiac remodeling secondary to chronic volume overload in female rats. J Appl Physiol. 2005;99:1378-1383.
85. Stauffer BL, Konhilas JP, Luczak ED, Leinwand LA. Soy diet worsens heart disease in mice. J Clin Invest. 2006;116:209-216.
86. Giardina EG. Heart disease in women. Int J Fertil Womens Med. 2000;45:350-357.
87. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 2005;26:1585-1595.
88. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475-480.
89. Nuedling S, Karas RH, Mendelsohn ME, Katzenellenbogen JA, Katzenellenbogen BS, Meyer R, Vetter H, Grohe C. Activation of estrogen receptor beta is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Lett. 2001;502:103-108.
90. Camper-Kirby D, Welch S, Walker A, Shiraishi I, Setchell KDR, Schaefer E, Kajstura J, Anversa P, Sussman MA. Myocardial Akt activation and gender. Increased nuclear activity in females versus males. Circ Res. 2001;88:1020-1027.
91. Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH. 17Beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res. 2004;95:692-699.
92. Nuedling S, van Eickels M, Allera A, Doevendans P, Meyer R, Vetter H, Grohe C. 17 Beta-estradiol regulates the expression of endothelin receptor type B in the heart. Br J Pharmacol. 2003;140:195-201.
93. Johnson BD, Zheng W, Korach KS, Scheuer T, Catterall WA, Rubanyi GM. Increased expression of the cardiac L-type calcium channel in estrogen receptor-deficient mice. J Gen Physiol. 1997;110:135-140.
94. Xu Y, Arenas IA, Armstrong SJ, Plahta WC, Xu H, Davidge ST. Estrogen improves cardiac recovery after ischemia/reperfusion by decreasing tumor necrosis factor-alpha. Cardiovasc Res. 2006;69:836-844.
95. Gallagher PE, Li P, Lenhart JR, Chappell MC, Brosnihan KB. Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension. 1999;33:323-328.
96. Nickenig G, Baumer AT, Grohe C, Kahlert S, Strehlow K, Rosenkranz S, Stablein A, Beckers F, Smits JF, Daemen MJ, Vetter H, Bohm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998;97:2197-2201.